WES also showed that the TMB in 3 patients (UH2, UH3, and UH6) was lower than 12 mutations/megabase pair (TCGA lower bound of CRC hypermutated phenotype23) despite negative MLH1 and PMS2 immunostaining and consistent with resistance to treatment (Supplementary Table 1). This evidence concerns the gene PMS2 and colorectal carcinoma.